Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 13;25(4):2245.
doi: 10.3390/ijms25042245.

Long-Term Outcomes after Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B

Tomohiro Nishikawa  1 , Masahiro Matsui  1 , Saori Onishi  1 , Kosuke Ushiro  1 , Akira Asai  1 , Soo-Ki Kim  2 , Hiroki Nishikawa  1
Affiliations

Long-Term Outcomes after Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B

Tomohiro Nishikawa et al. Int J Mol Sci. .

Abstract

We sought to determine the long-term outcomes of chronic hepatitis B (CHB) cases switching to tenofovir alafenamide (TAF, n = 104, median age = 63.5 years). Data at switching to TAF (baseline) and those at 1, 2, 3, 4, and 5 years from switching to TAF were compared. At baseline, HB envelop antigen (HBeAg) seropositivity was found in 20 patients (19.2%), and undetectable HBV-DNA in 77 patients (74.0%). Percentage of detectable HBV-DNA significantly reduced at any time point. HB surface antigen (HBsAg) levels significantly reduced at 3, 4, and 5 years. The percentage of HBeAg seropositivity significantly reduced at 5 years. HB core related antigen levels did not significantly change. In patients with baseline HbeAg seropositivity, HbsAg levels significantly reduced at any time point, and a similar trend was found in patients without HBeAg seropositivity. In patients with baseline FIB4 index >1.85, HBsAg levels significantly reduced at 3, 4, and 5 years, and in patients with baseline FIB4 index <1.85, HBsAg levels significantly reduced at any time point. The estimated glomerular filtration rate significantly reduced only at 5 years. The discontinuation rate owing to the side effects of TAF was 0%. In conclusion, switching to TAF therapy in patients with CHB may be effective and safe at least up to 5 years.

Keywords: chronic hepatitis B; efficacy; safety; switch; tenofovir alafenamide.

PubMed Disclaimer

Conflict of interest statement

None of the authors has any conflicts of interest to declare.

Figures

Figure 1
Figure 1
Changes in ALT levels over time.
Figure 2
Figure 2
Changes in FIB4 index over time.
Figure 3
Figure 3
Changes in eGFR levels over time.
Figure 4
Figure 4
Changes in HBsAg levels over time.
Figure 5
Figure 5
Changes in the percentage of detectable HBV-DNA over time.
Figure 6
Figure 6
Changes in the percentage of HBeAg seropositivity over time.
Figure 7
Figure 7
Changes in the distribution of HBcrAg levels over time. Pearson’s χ-square test was used for between-group comparisons.
Figure 8
Figure 8
(A) Changes in HBsAg levels over time in patients with baseline HBeAg seropositivity at switching to TAF. (B) Changes in HBsAg levels over time in patients without baseline HBeAg seropositivity at switching to TAF.
Figure 9
Figure 9
(A) Changes in HBsAg levels over time in patients with baseline FIB4 index >1.85 at switching to TAF. (B) Changes in HBsAg levels over time in patients with baseline FIB4 index <1.85 at switching to TAF.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. GBD 2019 Hepatitis B Collaborators Global, regional, and national burden of hepatitis B, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol. Hepatol. 2022;7:796–829. doi: 10.1016/S2468-1253(22)00124-8. - DOI - PMC - PubMed
    1. Jeng W.J., Papatheodoridis G.V., Lok A.S.F. Hepatitis B. Lancet. 2023;401:1039–1052. doi: 10.1016/S0140-6736(22)01468-4. - DOI - PubMed
    1. Nishikawa H., Nishijima N., Arimoto A., Inuzuka T., Kita R., Kimura T., Osaki Y. Effect of nucleoside analog use in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol. Res. 2014;44:608–620. doi: 10.1111/hepr.12169. - DOI - PubMed
    1. Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update. Hepatol. Res. 2020;50:892–923. doi: 10.1111/hepr.13504. - DOI - PubMed
    1. Lampertico P., Buti M., Fung S., Ahn S.H., Chuang W.L., Tak W.Y., Ramji A., Chen C.Y., Tam E., Bae H., et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: A randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol. Hepatol. 2020;5:441–453. doi: 10.1016/S2468-1253(19)30421-2. - DOI - PubMed

LinkOut - more resources